CompletedInterventionalPhase 2Last updated Feb 15, 2013

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia

Overview

ClinicalTrials.gov ID: NCT00300963
Lead Sponsor: GlaxoSmithKlineINDUSTRY
Brief Summary: The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Dec 2004
Primary Completion Date: Oct 2005Actual
Completion Date: Oct 2005Actual

Study Record Dates

First Submitted: Mar 7, 2006
First Submitted that Met QC Criteria: Mar 7, 2006
First Posted: Mar 10, 2006Estimated
Last Update Submitted that Met QC Criteria: Feb 13, 2013
Last Update Posted: Feb 15, 2013Estimated
Last Verified: Feb 2013

NCT00103727Completed

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

NCT00049946Completed

Schizophrenia Study In Adults

NCT00249132Completed

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

NCT00249119Completed

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia

NCT04512066Completed

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT00435370Completed

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia